15 November 2022
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Confirmation of Interim Results
Investor Presentation
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, confirms it will announce its interim results for the six months to 30 September 2022 on 24 November 2022.
Investor presentation
Jag Grewal, Chief Executive Officer, and Chris Lea, Chief Financial Officer, will provide a live presentation relating to the Company's Interim Results via the Investor Meet Company platform on 24 November 2022 at 4:30pm GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics Group Plc via:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
Investors who already follow Omega Diagnostics Group Plc on the Investor Meet Company platform will automatically be invited.
Contacts:
| Omega Diagnostics Group PLC | |||
| Jag Grewal, Chief Executive Officer | via Walbrook PR | ||
| Chris Lea, Chief Financial Officer | | ||
| | | ||
| | | ||
| finnCap Ltd | Tel: 020 7220 0500 | ||
| Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance) | | ||
| Alice Lane/Charlotte Sutcliffe (ECM) | | ||
| | | ||
| | | ||
| Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com | ||
| Paul McManus | Mob: 07980 541 893 | ||
| Lianne Applegarth | Mob: 07584 391 303 | ||
| Sam Allen | Mob: 07502 558 258 | ||
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.